Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Changzhi
Clinical trial register · China

Clinical Trials in Changzhi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19282 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:17 UTC
19282
Studies in scope
all four open statuses
11840
Recruiting now
open to new participants
2032
Lead sponsors
across recruiting studies
Top sites
Beijing 5606 Shanghai 3892 Guangzhou 3359 Hangzhou 1833 Wuhan 1342

Trials with a site in Changzhi

27 of 19282 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
AstraZeneca
Phase 3
140
Beijing, Bengbu, Changchun, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou
2026-10-09
Recruiting
AstraZeneca
Not applicable
1,000
Anyang, Baoding, Beijing, Cangzhou, Changzhi, Chengdu, Fuzhou, Guangzhou
2026-06-02
Not yet open
Sinovac Biotech Co., Ltd
Phase 1
60
Changzhi
2026-03-09
Recruiting
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
NCT07175493Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome
DrugCM336
Keymed Biosciences Co.Ltd
Phase 1/2
158
Zhengzhou, Changzhi, Tianjin
2025-11-18
Recruiting
Xuanwu Hospital, Beijing
Not applicable
750
Guangdong, Baotou, Beijing, Bozhou, Changsha, Changzhi, Changzhou, Chifeng
2025-10-24
Active, closed
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
NCT07907965Diabetic Kidney Disease (DKD), Type 2 Diabetes, Albuminuria
Beijing University of Chinese Medicine
Phase 2
15
Changzhi
2025-10-20
Recruiting
AstraZeneca
Phase 2
100
Beijing, Changchun, Changzhi, Chengdu, Fuzhou, Hangzhou, Kunming, Qingdao
2025-07-17
Not yet open
Beijing 302 Hospital
Observational
2,000
Ankang, Anyang, Beihai, Beijing, Binzhou, Changzhi, Changzhou, Chengdu
2025-05-01
Recruiting
Daiichi Sankyo
Observational
260
Beijing, Changchun, Changzhi, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei
2025-02-27
Recruiting
Chinese PLA General Hospital
Phase 1/2
30
Beijing, Changzhi, Tianjin
2025-02-15
Recruiting
Changzhi People's Hospital Affiliated to Changzhi Medical College
Observational
170
Changzhi
2025-01-01
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Baise City, Beijing, Bengbu, Changchun, Changsha, Changzhi, Changzhou, Chengdu
2024-11-22
Active, closed
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
NCT06494241Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms
AstraZeneca
Observational
1,000
Anning, Anqing, Changzhi, Daqing, Dazhou, Dazhu, Dingzhou, Ganzhou
2024-11-22
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan
2024-08-30
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Anshan, Beijing, Changzhi, Chaoyang, Chengdu, Chifeng, Chongqing, Foshan
2024-08-30
Recruiting
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
60
Beijing, Changsha, Changzhi, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei
2024-07-17
Active, closed
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
240
Langfang, Xingtai, Zhengzhou, Jingzhou, Wuhan, Jinan, Liaocheng, Changzhi
2024-03-24
Recruiting
AstraZeneca
Phase 3
5,250
Anning, Anyang, Baotou, Beijing, Changsha, Changzhi, Chengdu, Chifeng
2024-02-21
Recruiting
Qilu Pharmaceutical Co., Ltd.
Phase 3
270
Bengbu, Bozhou, Hefei, Beijing, Fuzhou, Dalian, Shanghai, Changzhi
2023-12-25
Recruiting
China-Japan Friendship Hospital
Phase 4
336
Beijing, Baoding, Qinhuangdao, Gongyi, Yangzhou, Jining, Qingdao, Changzhi
2023-03-29
Recruiting
C2 Esophageal Squamous Epithelium Dysplasia
NCT05349240Esophageal Squamous Epithelium Dysplasia
Pentax Medical
Not applicable
129
Beijing, Changchun, Changzhi, Shijiazhuang
2022-11-18
Recruiting
Second Xiangya Hospital of Central South University
Observational
20,000
Lanzhou, Shenzhen, Haikou, Harbin, Luoyang, Changsha, Nanjing, Changzhi
2022-01-01
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Beijing, Bengbu, Changsha, Changzhi, Changzhou, Chengdu, Fuzhou, Guangzhou
2021-12-02
Active, closed
AstraZeneca
Phase 3
640
Anyang, Beijing, Bengbu, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou
2020-10-19
Active, closed
Ruijin Hospital
Phase 2/3
580
Baoding, Beijing, Changsha, Changzhi, Chengdu, Guiyang, Haikou, Hangzhou
2019-12-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
6,000
Guilin, Changzhi, Yuncheng, Mianyang
2019-06-26
Recruiting
Chinese PD Registry
NCT03887663Parkinson Disease
Xiangya Hospital of Central South University
Observational
3,000
Changzhi
2017-02-01
Rows per page Showing 1–27 of 27
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-china/city/changzhi

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,282 studies in total at the last sync on 15 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 27 of those studies with a site in Changzhi.

How many clinical trials are recruiting in Changzhi?

16 of the 27 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:17 UTC sync. A further 2 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changzhi), 27 studies
PhaseStudiesRecruitingShare
Phase 39433.3%
Observational6422.2%
Phase 24214.8%
Not applicable3311.1%
Phase 1/2227.4%
Phase 1103.7%
Phase 2/3103.7%
Phase 4113.7%

Most active sponsors

Lead sponsors with the most studies (Changzhi)
Lead sponsorStudiesRecruiting
AstraZeneca64
Alpine Immune Sciences Inc, A Subsidiary of Vertex10
Beijing 302 Hospital10
Beijing University of Chinese Medicine10
Boehringer Ingelheim10
Changzhi People's Hospital Affiliated to Changzhi Medical College11
China-Japan Friendship Hospital11
Chinese PLA General Hospital11
Daiichi Sankyo11
Genrix (Shanghai) Biopharmaceutical Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.